{'fraction_non_alphanumeric': 0.012244897959183673, 'fraction_numerical': 0.0016326530612244899, 'mean_word_length': 6.2976190476190474, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evolving Role of Pharmacogenetic Biomarkers to Predict Drug-Induced Hematological Disorders.

Drug induced haematological disorders constitute up to 30% of all blood dyscrasias seen in the clinic. Hematologic toxicity from drugs may range from life threatening marrow aplasia, agranulocytosis, haemolysis, thrombosis to mild leukopenia and thrombocytopenia. Pathophysiologic mechanisms underlying these disorders vary from an extension of the pharmacological effect of the drug to idiosyncratic and immune mediated reactions. Predicting these reactions is often difficult and this makes clinical decision making challenging. Evidence supporting the role of pharmacogenomics in the management of these disorders in clinical practise is rapidly evolving. Despite the Clinical Pharmacology Implementation Consortium and Pharmacogenomics Knowledge Base recommendations, few tests have been incorporated into routine practice. This review aims to provide a comprehensive summary of the various drugs which are implicated for the haematological adverse events, their underlying mechanisms and the current evidence and practical recommendations to incorporate pharmacogenomic testing in clinical care for predicting these disorders.